- Home
- SITC vs ABEO Comparison
SITC vs ABEO Comparison
Compare SITC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | ABEO |
|---|---|---|
| Founded | 1965 | 1974 |
| Country | United States | United States |
| Employees | 172 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.9M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SITC | ABEO |
|---|---|---|
| Price | $5.87 | $5.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.83 | ★ $18.75 |
| AVG Volume (30 Days) | 686.0K | ★ 948.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 112.13% | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | $12.09 | ★ $3.80 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $5.85 | $3.93 |
| 52 Week High | $13.27 | $7.54 |
Technical Indicators
Market Signals| Indicator | SITC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 47.03 |
| Support Level | N/A | $4.87 |
| Resistance Level | $6.64 | $5.60 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 3.80 | 33.63 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.